Addendum

Tafamidis (transthyretin amyloidosis with cardiomyopathy) - Addendum to Commission A20-102

Report documents

Indication:

Wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) in adult patients

Result of dossier assessment:

Patients with NYHA class I + II cardiac failure: hint of major added benefit.

Patients with NYHA class III cardiac failure: hint of considerable added benefit.

Federal Joint Committee (G-BA)

2021.05.20 A G-BA decision was published.

Project no.: A21-42
Commission: Commission awarded on 08.04.2021 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Heart and circulation
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.